Poorly differentiated thyroid carcinoma (PDTC) and anaplastic (undifferentiated) thyroid carcinoma (ATC) comprise a small subset of thyroid tumors that are associated with a poor prognosis and account for a significant portion of the morbidity and mortality related to thyroid cancer. Since management strategies vary between these two entities, it is important for clinicians to be able to differentiate PDTC from ATC.
Methods
We reviewed the literature on PDTC and ATC and compared clinical and histopathologic features important in defining the disease process.
Results
Both PDTC and ATC display aggressive behavior with increased locoregional and distant disease. In most cases, patients are older and have large, locally advanced tumors. PDTC may represent an intermediate entity in the progression of well-differentiated thyroid carcinoma to ATC. The use of surgical management may be curative or palliative and differs between PDTC and ATC. The roles of radiotherapy and chemotherapy have not been well described.
Conclusions
PDTC and ATC are rare diseases that carry a poor prognosis. Recognition of their different clinicopathologic features is important to the optimal management of these tumors.
References
1.
ShahaA.R.Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope.2004; 114: 393–402.
2.
SakamotoA., KasaiN., SuganoH.Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer.1983; 52: 1849–1855.
3.
CarcangiuM.L., ZampiG., RosaiJ.Poorly differentiated (“insular”) thyroid carcinoma: a reinterpretation of Langhans’ “wuchernde Struma.”Am J Surg Pathol.1984; 8: 655–668.
4.
NishidaT., KatayamaS., TsujimotoM.Clinicopathological significance of poorly differentiated thyroid carcinoma. Am J Surg Pathol.1999; 23: 205–211.
5.
Sobrinho-SimoesM., SambadeC., FonsecaE.Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol.2002; 10: 123–131.
6.
CarcangiuM.L., BianchiS.Diffuse sclerosing variant of papillary thyroid carcinoma: clinicopathologic study of 15 cases. Am J Surg Pathol.1989; 13: 1041–1049.
7.
PilottiS., ColliniP., ManzariA.Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns?Semin Diagn Pathol.1995; 12: 249–255.
8.
Sobrinho-SimoesM., NeslandJ.M., JohannessenJ.V.Columnar-cell carcinoma. Another variant of poorly differentiated carcinoma of the thyroid. Am J Clin Pathol.1988; 89: 264–267.
9.
AkslenL.A., LiVolsiV.A.Poorly differentiated thyroid carcinoma: it is important. Am J Surg Pathol.2000; 24: 310–313.
10.
NikiforovY.E., EricksonL.A., NikiforovaM.N.Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol.2001; 25: 1478–1484.
11.
NikiforovY., GneppD.R.Pediatric thyroid cancer after the Chernobyl disaster: pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer.1994; 74: 748–666.
12.
NikiforovY., GneppD.R., FaginJ.A.Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab.1996; 81: 9–14.
13.
YuntaP.J., PonceJ.L., PrietoM.The importance of a tumor capsule in columnar cell thyroid carcinoma: a report of two cases and review of the literature. Thyroid.1999; 9: 815–819.
14.
BurmanK.D., RingelM.D., WartofskyL.Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am.1996; 25: 49–68.
15.
LivolsiV.A.Surgical Pathology of the Thyroid.Philadelphia, Pa: Saunders; 1990.
16.
LanghansT.Uber die epithelialen formen der malignen struma. Virchows Arch A Pathol Anat.1907; 189: 69–188.
17.
HedingerC.E.Thyroid Cancer.Berlin, New York: Springer; 1969.
18.
MeissnerW.A., WarrenS.Tumors of the Thyroid Gland.Washington, DC: Armed Forces Institute of Pathology; 1969.
19.
WoolnerL.B., BeahrsO.H., BlackB.M.Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg.1961; 102: 354–387.
20.
AlbaredaM., Puig-DomingoM., WengrowiczS.Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid.1998; 8: 385–391.
21.
PapottiM., Botto MiccaF., FaveroA.Poorly differentiated thyroid carcinomas with primordial cell component: a group of aggressive lesions sharing insular, trabecular, and solid patterns. Am J Surg Pathol.1993; 17: 291–301.
22.
PilottiS., ColliniP., MarianiL.Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol.1997; 21: 1466–1473.
23.
HwangT.S., SuhJ.S., KimY.I.Poorly differentiated carcinoma of the thyroid retrospective clinical and morphologic evaluation. J Korean Med Sci.1990; 5: 47–52.
24.
FlynnS.D., FormanB.H., StewartA.F.Poorly differentiated (“insular”) carcinoma of the thyroid gland: an aggressive subset of differentiated thyroid neoplasms. Surgery.1988; 104: 963–970.
25.
LamK.Y., LoC.Y., ChanK.W.Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg.2000; 231: 329–338.
26.
MachensA., HinzeR., LautenschlagerC.Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg.2001; 136: 941–944.
27.
TakeuchiY., DaaT., KashimaK.Mutations of p53 in thyroid carcinoma with an insular component. Thyroid.1999; 9: 377–381.
28.
KilleenR.M., BarnesL., WatsonC.G.Poorly differentiated (‘insular’) thyroid carcinoma: report of two cases and review of the literature. Arch Otolaryngol Head Neck Surg.1990; 116: 1082–1086.
29.
van den BrekelM.W., HekkenbergR.J., AsaS.L.Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope.1997; 107: 254–259.
30.
RodriguezJ.M., ParrillaP., MorenoA.Insular carcinoma: an infrequent subtype of thyroid cancer. J Am Coll Surg.1998; 187: 503–508.
31.
AshfaqR., VuitchF., DelgadoR.Papillary and follicular thyroid carcinomas with an insular component. Cancer.1994; 73: 416–423.
32.
SasakiA., DaaT., KashimaK.Insular component as a risk factor of thyroid carcinoma. Pathol Int.1996; 46: 939–946.
33.
PietribiasiF., SapinoA., PapottiM.Cytologic features of poorly differentiated “insular” carcinoma of the thyroid, as revealed by fine-needle aspiration biopsy. Am J Clin Pathol.1990; 94: 687–692.
34.
PilottiS., ColliniP., Del BoR.A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol.1994; 18: 1054–1064.
35.
SywakM., PasiekaJ.L., OgilvieT.A review of thyroid cancer with intermediate differentiation. J Surg Oncol.2004; 86: 44–54.
36.
WreesmannV.B., GhosseinR.A., PatelS.G.Genome-wide appraisal of thyroid cancer progression. Am J Pathol.2002; 161: 1549–1556.
37.
DecaussinM., BernardM.H., AdeleineP.Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol.2002; 26: 1007–1015.
38.
JustinE.P., SeaboldJ.E., RobinsonR.A.Insular carcinoma: a distinct thyroid carcinoma with associated iodine-131 localization. J Nucl Med.1991; 32: 1358–1363.
39.
BrierleyJ.D., TsangR.W.External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol.1999; 16: 42–49.
40.
AsakawaH., KobayashiT., KomoikeY.Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res.1997; 17: 2757–2762.
41.
WangW., MacapinlacH., LarsonS.M.[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab.1999; 84: 2291–2302.
42.
WangW., LarsonS.M., FazzariM.Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab.2000; 85: 1107–1113.
43.
GillilandF.D., HuntW.C., MorrisD.M.Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer.1997; 79: 564–573.
44.
NelC.J., van HeerdenJ.A., GoellnerJ.R.Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc.1985; 60: 51–58.
45.
VenkateshY.S., OrdonezN.G., SchultzP.N.Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer.1990; 66: 321–330.
46.
LoC.Y., LamK.Y., WanK.Y.Anaplastic carcinoma of the thyroid. Am J Surg.1999; 177: 337–339.
47.
TanR.K., FinleyRKIII, DriscollD.Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck.1995; 17: 41–48.
48.
SchaeferC.J.Long-term survival in anaplastic thyroid cancer. Md Med J.1988; 37: 873–874.
HoltingT., MollerP., TschaharganeC.Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. World J Surg.1990; 14: 291–295.
51.
ToblerA., MaurerR., HedingerC.E.Undifferentiated thyroid tumors of diffuse small cell type. Histological and immunohistochemical evidence for their lymphomatous nature. Virchows Arch A Pathol Anat Histopathol.1984; 404: 117–126.
52.
MyskowM.W., KrajewskiA.S., DewarA.E.The role of immunoperoxidase techniques on paraffin embedded tissue in determining the histogenesis of undifferentiated thyroid neoplasms. Clin Endocrinol (Oxf).1986; 24: 335–341.
53.
BakiriF., DjemliF.K., MokraneL.A.The relative roles of endemic goiter and socioeconomic development status in the prognosis of thyroid carcinoma. Cancer.1998; 82: 1146–1153.
54.
PetterssonB., ColemanM.P., RonE.Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer.1996; 65: 13–19.
55.
McIverB., HayI.D., GiuffridaD.F.Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery.2001; 130: 1028–1034.
56.
DemeterJ.G., De JongS.A., LawrenceA.M.Anaplastic thyroid carcinoma: risk factors and outcome. Surgery.1991; 110: 956–963.
FaginJ.A.Molecular genetics of human thyroid neoplasms. Annu Rev Med.1994; 45: 45–52.
59.
CarcangiuM.L., SteeperT., ZampiG.Anaplastic thyroid carcinoma: a study of 70 cases. Am J Clin Pathol.1985; 83: 135–158.
60.
NishiyamaR.H., DunnE.L., ThompsonN.W.Anaplastic spindle-cell and giant-cell tumors of the thyroid gland. Cancer.1972; 30: 113–127.
61.
IbanezM.L., RussellW.O., Albores-SaavedraJ.Thyroid carcinoma: biologic behavior and mortality. Postmortem findings in 42 cases, including 27 in which the disease was fatal. Cancer.1966; 19: 1039–1052.
62.
Moreno EgeaA., Rodriguez GonzalezJ.M., Sola PerezJ.Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol.1993; 19: 517–521.
63.
CohenY., XingM., MamboE.BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst.2003; 95: 625–627.
64.
XingM.BRAF mutation in thyroid cancer. Endocr Relat Cancer.2005; 12: 245–262.
XingM., VaskoV., TalliniG.BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab.2004; 89: 1365–1368.
67.
XuX., QuirosR.M., GattusoP.High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res.2003; 63: 4561–4567.
68.
PuxedduE., MorettiS., EliseiR.BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab.2004; 89: 2414–2420.
69.
QuirosR.M., DingH.G., GattusoP.Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer.2005; 103: 2261–2268.
70.
KnaufJ.A., MaX., SmithE.P.Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res.2005; 65: 4238–4245.
71.
PasiekaJ.L.Anaplastic cancer, lymphoma, and metastases of the thyroid gland. Surg Oncol Clin N Am.1998; 7: 707–720.
72.
KobayashiT., AsakawaH., UmeshitaK.Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck.1996; 18: 36–41.
73.
Pacheco-OjedaL.A., MartinezA.L., AlvarezM.Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg.2001; 86: 117–121.
74.
Us-KrasovecM., GolouhR., AuerspergM.Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol.1996; 40: 953–958.
75.
WolfB.C., SheahanK., DeCosteD.Immunohistochemical analysis of small cell tumors of the thyroid gland: an Eastern Cooperative Oncology Group study. Hum Pathol.1992; 23: 1252–1261.
76.
PoppeK., LahoutteT., EveraertH.The utility of multimodality imaging in anaplastic thyroid carcinoma. Thyroid.2004; 14: 981–982.
TennvallJ., LundellG., HallquistA.Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma: report on two protocols. The Swedish Anaplastic Thyroid Cancer Group. Cancer.1994; 74: 1348–1354.
79.
HadarT., MorC., ShveroJ.Anaplastic carcinoma of the thyroid. Eur J Surg Oncol.1993; 19: 511–516.
80.
GiuffridaD., GharibH.Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol.2000; 11: 1083–1089.
81.
HaighP.I., ItuarteP.H., WuH.S.Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer.2001; 91: 2335–2342.
82.
NilssonO., LindebergJ., ZedeniusJ.Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg.1998; 22: 725–730.
83.
JunorE.J., PaulJ., ReedN.S.Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol.1992; 18: 83–88.
84.
De CrevoisierR., BaudinE., BachelotA.Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys.2004; 60: 1137–1143.
85.
Thyroid Carcinoma Task Force.AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract.2001; 7: 202–220.
86.
PellitteriP.K., McCaffreyT.V.Endocrine Surgery of the Head and Neck.Clifton Park, NY: Thomson Delmar Learning; 2003.
87.
LevendagP.C., De PorreP.M., van PuttenW.L.Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys.1993; 26: 125–128.
88.
SimpsonW.J.Anaplastic thyroid carcinoma: a new approach. Can J Surg.1980; 23: 25–27.
89.
KimJ.H., LeeperR.D.Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy: a new approach. Cancer.1983; 52: 954–957.
90.
KimJ.H., LeeperR.D.Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer.1987; 60: 2372–2375.
91.
TennvallJ., LundellG., WahlbergP.Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer.2002; 86: 1848–1853.
92.
WongC.S., Van DykJ., SimpsonW.J.Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol.1991; 20: 3–9.
93.
ShimaokaK., SchoenfeldD.A., DeWysW.D.A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer.1985; 56: 2155–2160.
94.
AhujaS., ErnstH.Chemotherapy of thyroid carcinoma. J Endocrinol Invest.1987; 10: 303–310.
95.
De BesiP., BusnardoB., TosoS.Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest.1991; 14: 475–480.
96.
WilliamsS.D., BirchR., EinhornL.H.Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep.1986; 70: 405–407.
97.
AinK.B., EgorinM.J., DeSimoneP.A.Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid.2000; 10: 587–594.
98.
YeungS.C., XuG., PanJ.Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells. Cancer Res.2000; 60: 650–656.
99.
XuG., PanJ., MartinC.Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab.2001; 86: 1769–1777.
100.
SuginoK., ItoK., MimuraT.The important role of operations in the management of anaplastic thyroid carcinoma. Surgery.2002; 131: 245–248.
101.
BesicN., AuerspergM., Us-KrasovecM.Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol.2001; 27: 260–264.
102.
BlagosklonnyM.V., GiannakakouP., WojtowiczM.Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab.1998; 83: 2516–2522.
103.
NagayamaY., YokoiH., TakedaK.Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab.2000; 85: 4081–4086.
104.
FranzenA., HeldinN.E.BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochem Biophys Res Commun.2001; 285: 773–781.
105.
KotchetkovR., CinatlJ., KrivtchikA.A.Selective activity of BSRNase against anaplastic thyroid cancer. Anticancer Res.2001; 21: 1035–1042.
